Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Update

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a significant growth in short interest in February. As of February 27th, there was short interest totaling 2,795 shares, a growth of 388.6% from the February 12th total of 572 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 5,925 shares, the short-interest ratio is presently 0.5 days. Based on an average daily trading volume, of 5,925 shares, the short-interest ratio is presently 0.5 days. Approximately 0.3% of the shares of the stock are sold short.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Several hedge funds have recently modified their holdings of the company. IFP Advisors Inc raised its position in shares of Global X Genomics & Biotechnology ETF by 20.8% in the third quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock valued at $110,000 after buying an additional 489 shares during the last quarter. Creative Financial Designs Inc. ADV lifted its stake in shares of Global X Genomics & Biotechnology ETF by 4.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after buying an additional 481 shares during the period. U.S. Capital Wealth Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF during the fourth quarter worth approximately $575,000. Atria Investments Inc boosted its position in Global X Genomics & Biotechnology ETF by 12.6% during the second quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock worth $156,000 after acquiring an additional 2,073 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its stake in Global X Genomics & Biotechnology ETF by 30.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after acquiring an additional 4,615 shares during the period. 56.95% of the stock is owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Trading Down 2.4%

Shares of NASDAQ:GNOM traded down $1.07 on Thursday, hitting $43.93. The company had a trading volume of 5,266 shares, compared to its average volume of 9,560. Global X Genomics & Biotechnology ETF has a 52-week low of $27.20 and a 52-week high of $51.42. The business has a 50 day moving average of $47.10 and a 200 day moving average of $44.02. The company has a market cap of $47.88 million, a PE ratio of -18.77 and a beta of 1.22.

Global X Genomics & Biotechnology ETF Announces Dividend

The company also recently announced a dividend, which was paid on Wednesday, January 7th. Investors of record on Tuesday, December 30th were paid a $0.5912 dividend. The ex-dividend date of this dividend was Tuesday, December 30th. This represents a yield of 259.0%. Global X Genomics & Biotechnology ETF’s payout ratio is presently -26.50%.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.